When the Covid-19 pandemic hit, the then-Stanford professor was one of the loudest critics of lockdowns, school closures and ...

Novavax on Thursday tried to calm investors spooked by the delay of full approval of its COVID vaccine shot by U.S.

Senior leaders at the FDA began pushing Moderna and Pfizer to file for full, formal approval of their COVID vaccines for ...

Vinay Prasad, named to lead the FDA agency tasked with regulating vaccines and gene therapy, has made controversial comments ...

Vaccine maker Novavax is seeking to convert the 2022 emergency authorization of its Covid-19 vaccine into full approval. Yet ...

The independent experts will meet on May 22 to discuss updates to the COVID-19 vaccine for the upcoming season.

For years, U.S. vaccine experts have issued a universal recommendation for Covid vaccines. That could change soon.

Placebo testing has been part of the process since the 1940s. It’s unclear what additional measures would achieve — but it may slow development.

Vaccines using mRNA are currently being studied for a wide range of diseases, including cancer, cardiovascular disease, ...

Early COVID suppression could have prevented 180,000 UK deaths, study reveals … FDA, CDC pause chikungunya vaccine for adults ...

Novavax posts $667 million in Q1 2025 revenue and $2.93 EPS, boosted by Sanofi payments and APA terminations; full-year ...

(Reuters) - Novavax on Thursday tried to calm investors spooked by the delay of full approval of its COVID vaccine shot by U.S. regulators saying that it sees a pathway to resolving issues with ...